Clinical Trial Update: A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating mFOLFIRI plus MEK162 in patients with advanced RAS-mutant metastatic colorectal cancer; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• MEK162 (binimetinib)
• mFOLFIRI

Snippet

Sponsor: University of Utah | Conditions: Advanced KRAS Positive Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED